CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
[18F]F-Ara-Gdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03367962
NCT03367962Phase 1Completed
CompareCT.gov

Detection of Graft Versus Host Disease With [18F]F-AraG, a Positron Emission Tomography Tracer for Activated T Cells

CellSight Technologies, Inc.·interventional·Posted Dec 11, 2017·Updated Dec 8, 2025

In Brief

A Phase 1 clinical trial evaluating [18F]F-Ara-G for Graft Versus Host Disease. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PET scans will be compared to biopsy results to correlate T cell accumulation which is implicated in the disease. High risk patients will be followed to verify predictive potential of \[18F\]F-AraG.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft Versus Host Disease
CountriesUnited States
CollaboratorsStanford University, National Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 11, 2017
Enrollment StartMay 15, 2018
Primary CompletionJun 21, 2023
Study CompletionOct 21, 2023
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 8.6 years ago

Interventions

[18F]F-Ara-Gdrug

the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.